Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A2 | P43004 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23042389 | 0.87 | SLC1A2 (0.34) | SLC1A2 | |
| SCHEMBL4078899 | 0.87 | — | — | |
| Ammonia Solution, Strong SCHEMBL5232391 | 0.86 | MAPT (0.31) | — | |
| SCHEMBL27680982 | 0.83 | — | — | |
| SCHEMBL7368083 | 0.79 | GRM4 (0.31) | — | |
| SCHEMBL7444838 | 0.75 | — | — | |
| SCHEMBL5309327 | 0.74 | MAPT (0.37) | — | |
| SCHEMBL3919444 | 0.73 | ALDH1A1 (0.33) | — | |
| Carbamic Acid SCHEMBL8907484 | 0.71 | — | — | |
| SCHEMBL7014956 | 0.70 | MAPT (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010056907-A2 | COMPOUNDS THAT INDUCE PANCREATIC BETA-CELL EXPANSION | THE SCRIPPS RESEARCH INSTITUTE (US) | 2010-05-20 | — | — | WO | claimed |
| EP-1478627-A1 | METHOD | AstraZeneca AB (SE) | 2004-11-24 | — | — | EP | claimed |
| WO-2003062203-A1 | METHOD | ASTRAZENECA AB (SE) | 2003-07-31 | — | — | WO | claimed |
| WO-2012158568-A1 | COMPOUNDS FOR STEM CELL DIFFERENTIATION | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2012-11-22 | — | — | WO | disclosed |
| EP-2348855-A2 | SMALL MOLECULE COMPOUNDS FOR STEM CELL DIFFERENTIATION | Burnham Institute for Medical Research (US) | 2011-08-03 | — | — | EP | disclosed |
| EP-2252299-A1 | FUSED PYRIDONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | Merck Sharp & Dohme Corp. (US) | 2010-11-24 | — | — | EP | disclosed |
| WO-2010033643-A2 | SMALL MOLECULE COMPOUNDS FOR STEM CELL DIFFERENTIATION | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2010-03-25 | — | — | WO | disclosed |
| WO-2010002483-A1 | OPTIONALLY CONDENSED DIHYDRO PYRIDINE, DIHYDROPYRIMIDINE AND DIHYDRO PYRANE DERIVATIVES ACTING AS LATE SODIUM CHANNEL BLOCKERS | CV THERAPEUTICS, INC. (US) | 2010-01-07 | — | — | WO | disclosed |
| WO-2009102588-A1 | FUSED PYRIDONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK & CO., INC. (US) | 2009-08-20 | — | — | WO | disclosed |
| WO-2009006580-A1 | OPTIONALLY CONDENSED DIHYDROPYRIDINE, DIHYDROPYRIMIDINE AND DIHYDROPYRANE DERIVATIVES ACTING AS LATE SODIUM CHANNEL BLOCKERS | CV THERAPEUTICS, INC. (US) | 2009-01-08 | — | — | WO | disclosed |
| EP-1814554-A1 | CERTAIN COMPOUNDS, COMPOSITIONS, AND METHODS | Cytokinetics, Inc. (US) | 2007-08-08 | — | — | EP | disclosed |
| EP-1812080-A2 | GPR41 AND MODULATORS THEREOF FOR THE TREATMENT OF INSULIN-RELATED DISORDERS | Arena Pharmaceuticals, Inc. (US) | 2007-08-01 | — | — | EP | disclosed |
| WO-2006052566-A2 | GPR41 AND MODULATORS THEREOF FOR THE TREATMENT OF INSULIN-RELATED DISORDERS | ARENA PHARMACEUTICALS, INC. (US) | 2006-05-18 | — | — | WO | disclosed |
| WO-2006047537-A1 | CERTAIN COMPOUNDS, COMPOSITIONS, AND METHODS | CYTOKINETICS, INC. (US) | 2006-05-04 | — | — | WO | disclosed |
| EP-1278746-A2 | DIHYDROPYRIDINE COMPOUNDS AND METHODS OF USE | Abbott Laboratories (US) | 2003-01-29 | — | — | EP | disclosed |
| WO-2001083480-A2 | DIHYDROPYRIDINE COMPOUNDS AND METHODS OF USE | ABBOTT LABORATORIES (US) | 2001-11-08 | — | — | WO | disclosed |